JP2009517473A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517473A5
JP2009517473A5 JP2008543378A JP2008543378A JP2009517473A5 JP 2009517473 A5 JP2009517473 A5 JP 2009517473A5 JP 2008543378 A JP2008543378 A JP 2008543378A JP 2008543378 A JP2008543378 A JP 2008543378A JP 2009517473 A5 JP2009517473 A5 JP 2009517473A5
Authority
JP
Japan
Prior art keywords
bcaa
protein
individual
precursor
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008543378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517473A (ja
JP5260303B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/045497 external-priority patent/WO2007064618A1/en
Publication of JP2009517473A publication Critical patent/JP2009517473A/ja
Publication of JP2009517473A5 publication Critical patent/JP2009517473A5/ja
Application granted granted Critical
Publication of JP5260303B2 publication Critical patent/JP5260303B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008543378A 2005-11-30 2006-11-28 筋肉損失の治療のための方法 Expired - Fee Related JP5260303B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74109205P 2005-11-30 2005-11-30
US60/741,092 2005-11-30
US78094106P 2006-03-09 2006-03-09
US60/780,941 2006-03-09
PCT/US2006/045497 WO2007064618A1 (en) 2005-11-30 2006-11-28 Methods for the treatment of muscle loss

Publications (3)

Publication Number Publication Date
JP2009517473A JP2009517473A (ja) 2009-04-30
JP2009517473A5 true JP2009517473A5 (enExample) 2010-01-28
JP5260303B2 JP5260303B2 (ja) 2013-08-14

Family

ID=37806127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008543378A Expired - Fee Related JP5260303B2 (ja) 2005-11-30 2006-11-28 筋肉損失の治療のための方法

Country Status (17)

Country Link
US (1) US8329646B2 (enExample)
EP (1) EP1957061B1 (enExample)
JP (1) JP5260303B2 (enExample)
CN (1) CN101316582A (enExample)
AT (1) ATE508745T1 (enExample)
AU (1) AU2006320670B8 (enExample)
BR (1) BRPI0619179A2 (enExample)
CA (1) CA2631647A1 (enExample)
DK (1) DK1957061T3 (enExample)
ES (1) ES2363442T3 (enExample)
IL (1) IL191374A0 (enExample)
MY (1) MY147489A (enExample)
PT (1) PT1957061E (enExample)
RU (1) RU2414897C2 (enExample)
SG (1) SG163600A1 (enExample)
WO (1) WO2007064618A1 (enExample)
ZA (1) ZA200805657B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
BRPI0819759A2 (pt) * 2007-11-26 2015-05-05 Nestec Sa Composições e métodos para inibir a ativação da proteína quinase dependente de ds-rna e inibição de crescimento de tumor
ES2483735T3 (es) 2008-02-07 2014-08-07 Nestec S.A. Composiciones y métodos para influir en la recuperación después de una actividad física intensa
CA2719857C (en) * 2008-03-26 2019-08-06 Glanbia Nutritionals (Ireland) Ltd. Leucine-rich peptide compositions and methods for isolation
US20130236447A1 (en) * 2008-12-23 2013-09-12 Carmel-Haifa University Economic Corp., Ltd. Cognitive function
AU2011214465A1 (en) 2010-02-10 2012-08-30 Novartis Ag Methods and compounds for muscle growth
KR20140007926A (ko) * 2011-02-25 2014-01-20 메르크 파텐트 게엠베하 관절 및/또는 자세의 안정성을 증가시키기 위한 조성물
RU2454227C1 (ru) * 2011-04-05 2012-06-27 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Композиция для восстановления скелетных мышц и кости при скелетной травме
RU2017129378A (ru) 2011-07-15 2019-02-04 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
EP2813224A4 (en) * 2012-02-06 2015-06-24 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST IDIOPATHIC INFLAMMABLE MUSCLE DISEASES
WO2013148329A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Charged nutritive proteins and methods
JP2015518470A (ja) 2012-03-26 2015-07-02 プロニュートリア・インコーポレイテッドＰｒｏｎｕｔｒｉａ， Ｉｎｃ． 栄養タンパク質および方法
CA2868469A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments, proteins and methods
EP3715365A1 (en) 2012-03-26 2020-09-30 Axcella Health Inc. Nutritive fragments, proteins and methods
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
RU2517576C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Средство для профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
CA2912519A1 (en) 2013-04-16 2014-10-23 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of brain injury
US20160066610A1 (en) * 2013-05-01 2016-03-10 Abbott Laboratories Methods for enhancing aged muscle regeneration
CN103416760B (zh) * 2013-08-28 2014-09-10 山东卫康生物医药科技有限公司 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品
MX2016003944A (es) 2013-09-25 2016-12-09 Pronutria Biosciences Inc Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos.
KR101668074B1 (ko) * 2015-02-12 2016-10-21 전북대학교산학협력단 Ｐｋｒ 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물
CN105747214A (zh) * 2016-02-26 2016-07-13 四川安益生物科技有限公司 一种支链氨基酸组合物
CN110234334B (zh) * 2016-12-05 2024-02-06 大塚制药株式会社 肌肉萎缩抑制组合物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
CN107440126A (zh) * 2017-09-08 2017-12-08 天津活力达生物科技有限公司 一种缓解运动疲劳的蛋白粉及其制备方法
JP7418896B2 (ja) 2018-04-18 2024-01-22 インジニアス イングリーディエンツ，エルピー 筋成長および筋機能を促進するための組成物およびその使用法
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
EP3986557A1 (en) * 2019-06-20 2022-04-27 Société des Produits Nestlé S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids
IT201900010437A1 (it) * 2019-06-28 2020-12-28 Dompe Farm Spa Composizione per il trattamento del deperimento muscolare

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4677121A (en) 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4780475A (en) 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
JPH03264525A (ja) * 1990-03-14 1991-11-25 Otsuka Pharmaceut Factory Inc アミノ酸輸液
US6608109B2 (en) * 1991-11-20 2003-08-19 Allen Ann De Wees Composition comprising L-arginine as a muscle growth stimulant and use thereof
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP2002523448A (ja) * 1998-08-28 2002-07-30 サイオス インコーポレイテッド ｐ３８−αキナーゼのインヒビター
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
KR20020090214A (ko) 2000-02-01 2002-11-30 머슬테크 리서치 앤드 디벨롭먼트, 인크. 근육을 키우거나 강도를 늘리기 위한 α리포산계의보조식품
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
FR2833012B1 (fr) * 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US8703209B2 (en) 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20080058324A1 (en) 2004-08-25 2008-03-06 Santhera Pharmaceuticals (Schweiz) Ag Alpha-Keto Carbonyl Calpain Inhibitors
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
US7790688B2 (en) * 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly

Similar Documents

Publication Publication Date Title
JP2009517473A5 (enExample)
WO2007064618A8 (en) Methods for the treatment of muscle loss
JP2007527914A5 (enExample)
ZA200810125B (en) Pharmaceutical combination comprising 3- (3-dimethy-lamin0-1-ethyl-2-methyl-pr0pyl)-phenol and an NSAID
JP2005518433A5 (enExample)
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EP2982696A3 (en) Treatment of acute lymphoblastic leukemia
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
JP2011511805A5 (enExample)
BRPI0710682B8 (pt) combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol
JP2013510169A5 (enExample)
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
NO20082636L (no) Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
JP2009505991A5 (enExample)
EA200801890A1 (ru) Средство для лечения шума в ушах
WO2010098625A2 (ko) 약제학적 제제
JP2009523124A5 (enExample)
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
IS7899A (is) Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
JP2007230991A5 (enExample)
JP2008545616A5 (enExample)